bioAffinity Technologies Closes $4 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-The-Market
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) closed a previously announced registered direct offering of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 per share ($6.115 per pre-funded warrant), priced at-the-market under Nasdaq rules. The Company concurrently closed a private placement of warrants to purchase up to 980,072 shares of common stock at an exercise price of $6.122 per share, exercisable following stockholder approval and exp...
Key takeaways
Closed registered direct offering of common stock (or pre-funded warrants in lieu thereof) at $6.122 per share ($6.115 per pre-funded warrant), priced at-the-market under Nasdaq rules
Concurrent private placement of warrants to purchase up to 980,072 shares of common stock at an exercise price of $6.122 per share
Pre-funded warrants have an exercise price of $0.007 per share of common stock
Warrants will be exercisable following stockholder approval and expire five years from the date of stockholder approval
Gross proceeds of approximately $4 million before deducting placement agent fees and offering expenses
WallachBeth Capital, LLC acted as sole placement agent for the offering
Offered pursuant to shelf registration statement on Form S-3 (File No. 333-275608), effective November 27, 2023
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BIAF in real time
Get material earnings, filing, IR, and earnings-call alerts by email.